Participation in disease management programs and major adverse cardiac events in patients after acute myocardial

Christian Fischer1, Jens Höpner1, Saskia Hartwig1

  • 1Institute of Medical Epidemiology, Biometrics and Informatics, Medical Faculty of Martin Luther University Halle-Wittenberg, Magdeburger Straße 8, 06112, Halle (Saale), Germany.

Insights

Disease management programs (DMPs) did not reduce major adverse cardiac events (MACE) after acute myocardial infarction (AMI). However, cardiac rehabilitation (CR) participation significantly lowered MACE risk, highlighting CR

Area of Science:

  • Cardiology
  • Public Health
  • Health Services Research

Background:

  • Cardiovascular diseases remain a leading cause of death globally.
  • Acute myocardial infarction (AMI) mortality rates are declining, increasing focus on secondary prevention.
  • Disease Management Programs (DMPs) and Cardiac Rehabilitation (CR) are key outpatient strategies post-AMI in Germany.

Purpose of the Study:

  • To evaluate the effectiveness of DMPs and CR in reducing major adverse cardiac events (MACE) after AMI.
  • To analyze outcomes in a region with high cardiovascular disease burden.
  • To identify factors influencing DMP enrollment and their impact on patient outcomes.

Main Methods:

  • Utilized data from a regional AMI registry with a 2-year follow-up.
  • Assessed MACE in relation to CR and DMP participation.
  • Employed multivariable Cox regression to compare survival times.

Main Results:

  • DMP participation showed no significant association with reduced MACE risk (HR 1.03; 95% CI 0.72-1.48).
  • Smokers and obese patients were less likely to enroll in DMPs.
  • CR participation was associated with a significantly lower risk of MACE (HR 0.56; 95% CI 0.44-0.71).

Conclusions:

  • DMP participation post-AMI did not demonstrate a reduction in MACE.
  • Cardiac rehabilitation (CR) participation showed significant benefits in reducing MACE.
  • Further research is needed to explore confounding variables and optimize secondary prevention strategies.
Abstract

Related Concept Videos

Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
96
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
78
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
126
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
136
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
126
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
126